MedTrace Logo

A Study of XW003 Injection in Chinese Adolescents With Obesity

NCT07143227 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-05-20

No results posted yet for this study

Summary

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity

Conditions

Interventions

DRUG

XW003 injection

Subcutaneous injection

DRUG

placebo with matching volume

Subcutaneous injection

Sponsors & Collaborators

  • Hangzhou Sciwind Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wei Zhao, Dr · Qilu Hospital of Shandong University

  • Xinguo Hou, Dr · Qilu Hospital of Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-25
Primary Completion
2026-04-18
Completion
2026-04-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07143227 on ClinicalTrials.gov